Cargando…
Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time
(1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic drug–drug interactions (DDI). Identification of the nature of these DDIs, i.e., enzyme-based or/and transporter-based, is challenging, since most of these drugs are substrates of intestinal and/or hepatic cytoc...
Autores principales: | Malnoë, David, Fardel, Olivier, Le Corre, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696196/ https://www.ncbi.nlm.nih.gov/pubmed/36432682 http://dx.doi.org/10.3390/pharmaceutics14112493 |
Ejemplares similares
-
The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions
por: Pang, K. Sandy, et al.
Publicado: (2020) -
Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
por: Klatt, Sabine, et al.
Publicado: (2011) -
Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013) -
Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation
por: Dahan, Arik, et al.
Publicado: (2021) -
Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery
por: Hamman, J.H., et al.
Publicado: (2007)